Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227.

被引：22
|
作者：
Paz-Ares, Luis G.
Ciuleanu, Tudor-Eliade
Lee, Jong-Seok
Urban, Laszlo
Caro, Reyes Bernabe
Park, Keunchil
Sakai, Hiroshi
Ohe, Yuichiro
Nishio, Makoto
Pluzanski, Adam
Ramalingam, Suresh S.
Brahmer, Julie R.
Borghaei, Hossein
O'Byrne, Kenneth John
Hellmann, Matthew D.
Memaj, Arteid
Bushong, Judith
Tran, Phuong
Reck, Martin
机构：
[1] Univ Complutense, CNIO H12o Lung Canc Clin Res Unit, Hosp Univ 12 Octubre, Madrid, Spain
[2] CiberOnc, Madrid, Spain
[3] Inst Oncol Prof Dr Ion Chiricuta, Cluj Napoca, Romania
[4] UMF Iuliu Hatieganu, Cluj Napoca, Romania
[5] Seoul Natl Univ, Bundang Hosp, Seongnam, South Korea
[6] Matrai Gyogyint, Matrahaza, Hungary
[7] Hosp Univ Virgen Del Rocio, Inst Biomed Seville, Seville, Spain
[8] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[9] Saitama Canc Ctr, Saitama, Japan
[10] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan
[11] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
[12] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland
[13] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[14] Johns Hopkins Kimmel Canc Ctr, Baltimore, MD USA
[15] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[16] Princess Alexandra Hosp, Brisbane, Qld, Australia
[17] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[18] Bristol Myers Squibb, Princeton, NJ USA
[19] Bristol Myers Squibb, Springfield, PA USA
[20] German Ctr Lung Res, LungClin, Airway Res Ctr North, Grosshansdorf, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.9016
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9016
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227
    Schumann, C.
    Paz-Ares, L.
    Ciuleanu, T. -E
    Lee, J. -S
    Urban, L.
    Caro, Bernabe R.
    Park, K.
    Sakai, H.
    Ohe, Y.
    Nishio, M.
    Pluzanski, A.
    Ramalingam, S. S.
    Brahmer, J. R.
    Borghaei, H.
    O'Byrne, K. J.
    Hellmann, M. D.
    Memaj, A.
    Bushong, J.
    Tran, P.
    Reck, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 173 - 173
  • [2] Five-year survival outcomes with nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for metastatic non-small cell lung cancer (NSCLC): Results from CheckMate 227.
    Brahmer, Julie R.
    Lee, Jong-Seok
    Ciuleanu, Tudor-Eliade
    Caro, Reyes Bernabe
    Nishio, Makoto
    Urban, Lazio
    Audigier-Valette, Clarisse
    Lupinacci, Lorena
    Sangha, Randeep S.
    Paz-Ares, Luis G.
    Reck, Martin
    Borghaei, Hossein
    O'Byrne, Kenneth John
    Gupta, Ravi
    Bushong, Judith
    Li, Li
    Blum, Steven I.
    Eccles, Laura
    Ramalingam, Suresh S.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)
  • [3] Nivolumab (NIVO) plus ipilimumab (IPI) Versus Platinum-Doublet Chemotherapy (Chemo) as First-Line (1L) Treatment for Advanced Non-Small Cell Lung Cancer (aNSCLC): 3-year Update from CheckMate 227 Part 1
    Ramalingam, S. S.
    Ciuleanu, T. E.
    Pluzanski, A.
    Lee, J. -S.
    Schenker, M.
    Caro, R. B.
    Lee, K. H.
    Zurawski, B.
    Audigier-Valette, C.
    Provencio, M.
    Linardou, H.
    Kim, S. -W.
    Borghaei, H.
    Hellmann, M. D.
    O'Byrne, K. J.
    Paz-Ares, L. G.
    Reck, M.
    Nathan, F. E.
    Brahmer, J. R.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S2 - S3
  • [4] First-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) in Asian patients (pts) with advanced non-small cell lung cancer (aNSCLC) in CheckMate 227
    O'Byrne, K. J.
    Lee, K. H.
    Kim, S-W.
    Park, K.
    Nishio, M.
    Sakai, H.
    Ohe, Y.
    Fukuhara, T.
    Kang, J-H.
    Daga, H.
    Yu, C-J.
    Hotta, K.
    Tanaka, H.
    Takeda, M.
    Yokoyama, T.
    Nathan, F. E.
    Lee, J-S.
    ANNALS OF ONCOLOGY, 2020, 31 : S824 - S824
  • [5] First-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) plus chemotherapy (chemo) in Asian patients (pts) with advanced non-small cell lung cancer (NSCLC) from CheckMate 9LA
    John, T.
    Sakai, H.
    Ikeda, S.
    Cheng, Y.
    Kasahara, K.
    Sato, Y.
    Nakahara, Y.
    Takeda, M.
    Kaneda, H.
    Zhang, H.
    Maemondo, M.
    Minato, K.
    Hisada, T.
    Misumi, Y.
    Satouchi, M.
    Hotta, K.
    Li, A.
    Oukessou, A.
    Lu, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S847 - S848
  • [6] 5-year Survival Data in the First-line (1L) Treatment of advanced non-small cell Lung Cancer (mNSCLC) with Nivolumab (NIVO) plus Ipilimumab (IPI) vs Chemotherapy (chemo): Results of the CheckMate 227 Study
    Jaeschke, B.
    Brahmer, J. R.
    Lee, J. S.
    Ciuleanu, T. E.
    Caro, R. B.
    Nishio, M.
    Urban, L.
    Audigier-Valette, C.
    Lupinacci, L.
    Sangha, R.
    Paz-Ares, L. G.
    Reck, M.
    Borghaei, H.
    O'Byrne, K. J.
    Gupta, R. G.
    Bushong, J.
    Li, L.
    Blum, S. I.
    Eccles, L.
    Ramalingam, S. S.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 98 - 99
  • [7] Nivolumab (Nivo) plus Ipilimumab (Ipi) vs Platinum-Doublet Chemotherapy (Chemo) as First-line (1L) Treatment (Tx) for Advanced Non-Small Cell Lung Cancer (NSCLC): Safety Analysis and Patient-Reported Outcomes (PROs) From CheckMate 227.
    Reck, Martin
    Hellmann, Matthew David
    Paz-Ares, Luis G.
    Ramalingam, Suresh S.
    Brahmer, Julie R.
    O'Byrne, Kenneth John
    Bhagavatheeswaran, Prabhu
    Nathan, Faith Ellen
    Borghaei, Hossein
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] Nivolumab (NIVO) plus ipilimumab (IPI) versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1
    Thomas, M.
    Ramalingam, S. S.
    Ciuleanu, T. E.
    Pluzanski, A.
    Lee, J. -S.
    Schenker, M.
    Bernabe Caro, R.
    Lee, K. H.
    Zurawski, B.
    Audigier-Valette, C.
    Provencio, M.
    Linardou, H.
    Kim, S. -W.
    Borghaei, H.
    Hellmann, M. D.
    O'Byrne, K. J.
    Paz-Ares, L. G.
    Reck, M.
    Nathan, F. E.
    Brahmer, J. R.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 140 - 141
  • [9] Five-year survival outcomes with nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for metastatic non-small cell lung cancer (mNSCLC): Results from CheckMate 227
    Reck, Martin
    Brahmer, Julie R.
    Lee, Jong-Seok
    Ciuleanu, Tudor-Eliade
    Caro, Reyes Bernabe
    Nishio, Makoto
    Urban, Laszlo
    Audigier-Valette, Clarisse
    Lupinacci, Lorena
    Sangha, Randeep
    Paz-Ares, Luis
    Borghaei, Hossein
    O'byrne, Kenneth John
    Gupta, Ravi G.
    Bushong, Judith
    Li, Li
    Blum, Steven I.
    Eccles, Laura
    Ramalingam, Suresh S.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 162 - 162
  • [10] Nivolumab (NIVO) plus chemotherapy (chemo) or NIVO plus ipilimumab (IPI) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): first report of the CheckMate 648 study
    Greil, R.
    Chau, I
    Doki, Y.
    Ajani, J. A.
    Xu, J.
    Wyrwicz, L.
    Motoyama, S.
    Ogata, T.
    Kawakami, H.
    Hsu, C. -H
    Adenis, A.
    el Hajbi, F.
    Di Bartolomeo, M.
    Braghiroli, Ignez M.
    Holtved, E.
    Xynos, I
    Liu, X.
    Lei, M.
    Kondo, K.
    Kato, K.
    Kitagawa, Y.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 81 - 82
12345